sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY October 2015 | Archived Issues

FDA Requires Drug Interaction Studies for Kayexalate

Pharmacy Focus

The U.S. Food and Drug Administration is requiring the manufacturer of the hyperkalemia drug Kayexalate to conduct studies to investigate Kayexalate's potential to bind to other medications administered by mouth — drug interactions that could affect how well the other medications work.


Mark Your Calendar


Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.


Grand Rounds

Click here to view a schedule of all upcoming grand rounds.


Education Schedule

Click the PDF links below to see the Department of Surgery's education schedule.

Education Schedule - October 2015 (PDF)

Education Schedule - November 2015 (PDF)  


Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

FDA Requires Drug Interaction Studies for Kayexalate

Pharmacy Focus

The U.S. Food and Drug Administration is requiring the manufacturer of the hyperkalemia drug Kayexalate to conduct studies to investigate Kayexalate's potential to bind to other medications administered by mouth — drug interactions that could affect how well the other medications work.

To reduce the potential risk of binding, the FDA suggests that prescribers and patients consider separating Kayexalate dosing from other medications taken by mouth by at least six hours. Healthcare professionals should monitor blood levels or clinical response to the other medications when appropriate.

For more information, click here.